Alternatives to Bronchitol If You Can't Fill Your Prescription

Bronchitol (inhaled mannitol) plays an important role in managing cystic fibrosis by helping thin and clear mucus from the airways. But there are times when patients can't access it — whether due to insurance issues, access barriers, or failing the Bronchitol Tolerance Test. If you find yourself in that situation, there are alternatives worth discussing with your CF care team.

Important: Never stop or adjust your CF medications without talking to your pulmonologist or CF care team first. They can help you weigh the options based on your specific lung function, mutation type, and overall treatment plan.

Why Some Patients Can't Use Bronchitol

Before discussing alternatives, it helps to understand why a patient might not be able to use Bronchitol in the first place:

Failed Bronchitol Tolerance Test (BTT): About 8% of patients experience bronchospasm during the BTT and cannot be prescribed Bronchitol

Insurance denial: Prior authorization denied or step therapy requirements not yet met

Cost barrier: Approximately $3,826/month without insurance — unaffordable for many without assistance

Access issue: No specialty pharmacy available that dispenses Bronchitol in your area

Alternative 1: Pulmozyme (Dornase Alfa)

Pulmozyme (dornase alfa) is the most strongly recommended mucolytic for CF. Unlike Bronchitol, which works by drawing water into the airways, Pulmozyme acts like molecular scissors — it breaks apart DNA strands released by white blood cells in the thick CF mucus, reducing viscosity and improving clearance.

The Cystic Fibrosis Foundation guidelines strongly recommend dornase alfa for CF patients 6 years and older with moderate to severe disease. It's administered as a 2.5 mg nebulized solution once daily and must be refrigerated until use.

Key differences from Bronchitol: Requires a nebulizer and refrigeration; approved for ages 6+; different mechanism; strong CF Foundation evidence base

Alternative 2: Hypertonic Saline (7% or 3%)

Hypertonic saline is a concentrated salt solution inhaled via nebulizer to thin mucus in the lungs. Like Bronchitol, it works osmotically — the high salt content draws water into the airways. While not FDA-approved specifically for CF, it's widely recommended by the CF Foundation for patients 6 years and older.

Hypertonic saline is significantly less expensive than Bronchitol and is available in 3% and 7% concentrations (7% is more commonly used in CF). The European CF Society (2024) recognizes inhaled dry powder mannitol as an alternative to hypertonic saline — and vice versa — so the two are considered roughly comparable in terms of the airway hydration mechanism.

Key differences from Bronchitol: Requires a nebulizer; not FDA-approved for CF; much lower cost; available for patients 6+; cannot be combined with hypertonic saline while on Bronchitol (clinical trials excluded hypertonic saline)

Alternative 3: Trikafta (Elexacaftor/Tezacaftor/Ivacaftor)

Trikafta is a CFTR modulator triple-therapy that targets the underlying protein defect in CF, not just the symptoms. It's not a mucolytic like Bronchitol — instead, it helps the CFTR protein function better, which reduces the production of abnormally thick mucus in the first place. For patients with eligible CFTR mutations (most commonly F508del), Trikafta has been shown to dramatically improve lung function.

If you're not already on a CFTR modulator and your mutation profile qualifies, this is a conversation worth having with your CF specialist. Many patients on Trikafta have been able to reduce or discontinue some of their other CF therapies, including mucolytics, though you should never make that decision without your CF team.

Alternative 4: Inhaled Antibiotics (For Infection Component)

If part of your concern is managing chronic Pseudomonas aeruginosa lung infections — a very common issue in CF — inhaled antibiotics like TOBI (tobramycin), TOBI Podhaler, or Cayston (aztreonam) address the infection component of CF lung disease. These are not substitutes for Bronchitol's mucolytic role, but they are part of a complete CF management plan that your team may adjust while Bronchitol access is being sorted out.

What to Tell Your CF Team If You Can't Get Bronchitol

When you contact your CF care team about a Bronchitol access problem, be specific about what's happening:

Mention whether it's a prior authorization issue, cost issue, pharmacy availability issue, or BTT failure

Ask if hypertonic saline is an appropriate bridge therapy while access is being resolved

Ask about the Cystic Fibrosis Foundation's Compass service (1-844-COMPASS) for financial and access guidance

Ask your team to escalate the Bronchitol prior authorization if it's been pending for more than 7–10 business days

For help locating Bronchitol specifically, see our guide on How to Find Bronchitol In Stock Near You.

If cost is your barrier, read our guide on How to Save Money on Bronchitol in 2026 for copay assistance options.